These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36187401)

  • 61. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    Yahoo N; Dudek M; Knolle P; Heikenwälder M
    J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
    Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
    Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.
    Benhammou JN; Aby ES; Shirvanian G; Manansala K; Hussain SK; Tong MJ
    Sci Rep; 2020 Jun; 10(1):9902. PubMed ID: 32555268
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis.
    He J; Zhang X; Chen X; Xu Z; Chen X; Xu J
    Glob Med Genet; 2023 Sep; 10(3):144-158. PubMed ID: 37501756
    [No Abstract]   [Full Text] [Related]  

  • 67. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
    Ma C; Zhang Q; Greten TF
    FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges.
    Teng YX; Xie S; Guo PP; Deng ZJ; Zhang ZY; Gao W; Zhang WG; Zhong JH
    J Clin Transl Hepatol; 2022 Oct; 10(5):955-964. PubMed ID: 36304509
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.
    Karim MA; Singal AG; Kum HC; Lee YT; Park S; Rich NE; Noureddin M; Yang JD
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):670-680.e18. PubMed ID: 35307595
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort.
    Safcak D; Drazilova S; Gazda J; Andrasina I; Adamcova-Selcanova S; Barila R; Mego M; Rac M; Skladany L; Zigrai M; Janicko M; Jarcuska P
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300352
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    Anastasopoulos NT; Lianos GD; Tatsi V; Karampa A; Goussia A; Glantzounis GK
    Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1025-1033. PubMed ID: 32746645
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
    Koo SY; Park EJ; Lee CW
    Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance.
    Machado MV
    GE Port J Gastroenterol; 2024 Feb; 31(1):14-23. PubMed ID: 38314031
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
    Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
    Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.
    Tokushige K; Hyogo H; Nakajima T; Ono M; Kawaguchi T; Honda K; Eguchi Y; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Suzuki Y; Kogiso T; Karino Y; Munekage K; Kuromatsu R; Oeda S; Yanase M; Mori K; Ogawa Y; Seko Y; Takehara T; Itoh Y; Nakajima A; Kanemasa K; Nishino K; Masaki N; Takahashi H; Seike M; Torimura T; Saibara T; Toyota J; Chayama K; Hashimoto E
    J Gastroenterol; 2016 Jun; 51(6):586-96. PubMed ID: 26456168
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.